Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Cytokinetics Incorporated
KK3ACurrent price
47.4 EUR
-3.59 EUR (-7.06%)
Last closed
52 EUR
Company
www.cytokinetics.com
ISIN
US23282W6057
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
6 441 335 439 EUR
Yield for 12 month
+61.22 %
1Y
3Y
5Y
10Y
15Y
KK3A
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California. Address: 350 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
42.96 EURP/E ratio
–Dividend Yield
–Current Year
+7 141 166 EUR
Last Year
+89 703 665 EUR
Current Quarter
+439 092 EUR
Last Quarter
+236 142 EUR
Current Year
-305 934 943 EUR
Last Year
-138 674 233 EUR
Current Quarter
-79 803 714 EUR
Last Quarter
-75 250 628 EUR
Key Figures KK3A
1 year
3 years
5 years
10 years
EBITDA
-516 572 829 EUR
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-30.13 %
PEG Ratio
–
Return On Equity TTM
-572.15 %
Wall Street Target Price
42.96 EUR
Revenue TTM
3 253 641 EUR
Book Value
-0.12 EUR
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
22.5 %
Dividend Yield
–
Gross Profit TTM
-147 798 579 EUR
Earnings per share
-5.03 EUR
Diluted Eps TTM
-5.03 EUR
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics KK3A
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History KK3A
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:6
Payout Ratio
–
Last Split Date
25.06.2013
Dividend Date
–
Stock Valuation KK3A
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
2056.6634
Price Sales TTM
1979.7316
Enterprise Value EBITDA
-15.1401
Price Book MRQ
60.2264
Financials KK3A
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators KK3A
For 52 weeks
28.5 EUR
100.57 EUR
50 Day MA
49.38 EUR
Shares Short Prior Month
–
200 Day MA
55.6 EUR
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart